Histiocytoid cardiomyopathy (HC) is a rare but distinctive arrhythmogenic disorder characterized by incessant ventricular tachycardia, cardiomegaly, and often sudden death by age 2 years. The underlying genetic mechanism of HC has eluded researchers for decades. To further identify the potential molecular-genetic bases of HC, molecular analyses of HC hearts and hearts of age-matched controls were performed. Total RNA and genomic DNA were prepared from formalin-fixed, paraffin-embedded cardiac tissue from 12 cases of HC and 12 age-matched controls. To identify genes differentially expressed in HC, whole genome cDNA-mediated annealing, selection, extension, and ligation profiling was performed. TaqMan quantitative polymerase chain reaction confirmed changes in RNA expression. DNA copy number changes were measured by TaqMan copy number variant analysis. Analysis of differential gene expression in HC cases identified 2 significantly downregulated gene sets aligned sequentially along the genome. The 1st gene cluster consisted of genes S100A8, S100A9, and S100A12 at 1q21.3c, and the 2nd cluster consisted of genes IL1RL1(ST2), IL18R1, and IL18RAP at 2q12.1a. Strong decreases in interleukin 33 expression were also observed. Decreases in copy number of the S100A genes were confirmed by TaqMan copy number variant assays. S100A genes are downstream of the p38-MAPK pathway that can be activated by interleukin 33 signaling. These data suggest a model in which the interleukin 33-IL1RL1/p38-MAPK/ S100A8-S100A9 axis is downregulated in HC cardiac tissue and provide several candidate genes on 1q21.3c and 2q12.1a for inherited mutations that may predispose individuals to HC.
INTRODUCTION
Histiocytoid cardiomyopathy (HC) is a rare but distinctive arrhythmogenic disorder characterized by hamartomatous lesions of cardiac Purkinje cells. It primarily occurs in the 1st 2 years of life and has a female to male ratio of 3:1. Because of the female predominance, it was suggested that HC is an X-linked genetic disorder with prenatal lethality in males [1] . It predominantly affects Caucasians (80%) followed by African Americans (15%) and Latin Americans (3%); it is rare in infants of Asian origin [1] . Since its 1st description by Voth in 1962 [2] , HC has been published under many different synonyms, including arachnocytosis of the myocardium, infantile cardiomyopathy, infantile xanthomatous cardiomyopathy, oncocytic cardiomyopathy, focal lipid cardiomyopathy, isolated cardiac lipidosis, infantile cardiomyopathy with histiocytoid changes, myocardial or conduction system hamartoma, foamy myocardial transformation, and congenital cardiomyopathy.
A familial tendency was 1st reported by Bruton and colleagues in 1977 [3] and by Suarez and colleagues in 1987 [4] . Because of these theories and one of the author's personal experiences of a family with more than 1 child affected by HC, a worldwide registry of HC was started in 1999 after obtaining institutional review board approval. Data obtained from the reported cases and from the HC registry indicate a familial tendency of approximately 5% [5] .
Approximately 100 HC cases have been reported in the literature. Most of the published cases report a spectrum of arrhythmias; however, some infants have been misclassified as having sudden infant death This work was supported in part by the Emory Biomarker Service Center and Winship Cancer Center Support Grant (P30CA138292).
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The etiopathogenesis of HC has eluded researchers for decades, and numerous theories for the molecular/genetic basis of HC have been offered: cytochrome b mutation [8] , SRY (sex determining region Y)-box 6 (Sox6) mutation [9] , A8344G (MERRF) mitochondrial DNA mutation [10] , and 2 cases of X-linked dominant (Xp22) [11, 12] . As a 1st step in looking for the genetic basis of HC, we undertook collaborative testing of HC registry material with the authors of prior reports. Cytochrome b mutation testing (7 cases in Drs Cox and Schwartz's laboratory, Adelaide University, Adelaide, South Australia, Australia, and 20 cases in Dr DiMauro's laboratory, Columbia University, New York City, NY, USA) and Sox6 mutation testing (7 cases in Dr Murry Brilliant's laboratory, University of Arizona, Tuscon, AZ, USA) yielded negative results (personal communication). We therefore undertook whole genome expression analysis as a more comprehensive search for the pathogenesis of this disorder. The tested material included 4 cases from the previous collaborative work and 8 cases from the HC registry.
MATERIALS AND METHODS

HC registry
The HC registry collects clinical information, tissue samples, and family history from deidentified cases submitted from a variety of sources. The registry currently includes 105 cases. The majority of the tissue submitted resides in paraffin blocks, with only 2 cases submitted as frozen tissue.
Specimen collection
Twelve HC autopsy cases were selected based upon the amount of material available from the HC registry at Children's Healthcare of Atlanta, Atlanta, GA, USA. Four of the cases chosen were previously studied in the collaborative work, and the rest (8 cases) were material from the registry. More collaborative cases were not used due to complete exhaustion, damage, or loss of the material. Cases included 9 females and 3 males, ranging in age from 1 to 18 months. Additionally, 12 age-matched controls were collected from patients who died of noncardiac causes (6 females, 6 males). Histiocytoid cardiomyopathy lesions from the 12 study cases and subendocardial Purkinje fibers identified on careful examination of hematoxylin-eosinstained control sections were cut from the original paraffin blocks and re-embedded for study sectioning.
RNA preparation
Formalin-fixed, paraffin-embedded (FFPE) tissue sections (0.5 mm) of patient and matched control tissues were provided to the Emory Biomarker Service Center (EBSC) for RNA preparation using the Ambion RecoverAll MagMax methodology in a 96-well format on a MagMax Express Liquid Handling Robot (Applied Biosystems, Wichita, KS, USA). Total RNA was extracted from FFPE sections as previously described [13] using the RecoverAll kit (Applied Biosystems). Formalin-fixed, paraffin-embedded RNA was quantitated by nanodrop spectrophotometry and tested for RNA integrity and quality by Taqman analysis of the RPL13a ribosomal protein. Samples with sufficient yield (.500 ng), A 260 / A 280 ratio . 1.8, and RPL13a cycle threshold (C T ) values ,30 cycles were used for expression profiling.
DNA preparation
One-millimeter-diameter cores were taken from the HC lesions of paraffin-embedded blocks and from the subendocardial Purkinje areas of paraffin-embedded blocks and re-embedded. Formalin-fixed, paraffin-embedded sections were then cut from the re-embedded cores and deparaffinized in 1 mL of xylene at 50uC for 3 minutes, washed twice with 100% EtOH, and air dried for 15 minutes at room temperature. Cores were digested for 48 hours at 50uC in the presence of protease, and DNA purification was carried out using the Ambion RecoverAll Total Nucleic Acid Isolation Protocol and Kit (Applied Biosystems/Ambion, Austin, TX, USA), following the manufacturer's instructions. DNA concentration was determined using the Quant-iT PicoGreen dsDNA Kit (Invitrogen, Carlsbad, CA, USA) on a Gemini XPS spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA).
Expression profiling
A whole genome cDNA-mediated annealing, selection, extension, and ligation (WG-DASL) assay was performed according to the GoldenGate protocol using supplied reagents and following the manufacturer's instructions (Illumina, Inc, San Diego, CA, USA) as described [14, 15] . Briefly, total RNA extracted from the FFPE blocks was 1st converted to biotinylated cDNA using random hexamers and oligo-d(T)18 primers to ensure optimal coverage of the RNA fragments. This cDNA was then annealed to the WG-DASL assay pooled oligonucleotide probes followed by the extension and ligation steps of the assay. This assay pool incorporates 24 526 probes corresponding to 18 626 unique genes derived from RefSeq (Build 36.2, Release 22). Polymerase chain reaction (PCR) amplification of the annealed cDNA used Cy3 and Cy5 fluorescent-labeled universal PCR primers. The PCR product was then denatured and the single-stranded Cy3-and Cy5-labeled products captured on BeadChip arrays and scanned using an Illumnia BeadStation 500 Reader.
Data analysis
BeadStudio image analysis and data extraction software were used to extract raw data and provide preliminary analysis and quality control. On average, each oligonucleotide probe is represented by 30 beads per hybridized sample. Data were quantile normalized in BeadStudio and exported to spreadsheets for custom analysis. Unsupervised hierarchical clustering was performed using uncentered correlation and average linkage with gene and array centering and normalization using cluster and Java TreeView software as previously described [16] [17] [18] . Differentially expressed mRNAs were identified by significance analysis of microarrays software [19] . Significance analysis of microarrays analyses were performed as 2-class, unpaired analyses with 500 permutations, a 2-fold change threshold, and a false discovery rate ,1% as previously described [20] . Annotation files containing probe sequence and chromosomal location data were downloaded from the Illumina website. Using the annotation files data, probes from the WG-DASL annotation files were sorted along their chromosome locations, and consecutive probes with strong decreases in gene expression based on the SAM analysis (.2-fold) were identified.
Quantitative PCR mRNA validation Genes located in candidate deletion regions were validated by mRNA expression using an Applied Biosystems 7900 Instrument. TaqMan assays used for each validated gene and control are summarized in Supplementary Table 1 . Beta-glucuronidase served as an internal normalization control. The DC T method was used to quantitate the relative abundance of mRNA species for all reactions [21] .
TaqMan DNA copy number variation assay Genes located in the candidate deletion regions were also validated using changes in DNA copy number as measured by TaqMan copy number variation analysis. To determine if the TaqMan copy number assay could be used for FFPE samples, a pair of matching FFPE and freshfrozen normal control tissue samples were assayed. Equal copy numbers between FFPE and fresh-frozen normal control tissue were obtained for all assays tested. This pair of samples (unrelated to HC) was included in all assays and the fresh sample set as a calibrator (copy number 5 2).
Polymerase chain reaction primers were designed to amplify a short region within the target genes. Primer/ probes were selected so they were close to the probes used on the WG-DASL chip. A fluorescent reporter probe labeled with 6-carboxyfluorescein (FAM) was also synthesized to specifically anneal to the target. Similarly, a pair of PCR primers and a VIC-labeled probe was designed for the RNase P locus, which has a stable copy number and served as a normalization reference. The TaqMan assay was carried out on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Each of the 10-mL duplex real-time PCR reactions consisted of 10 ng of genomic DNA, 2.5 mL of TaqMan Genotyping Mastermix, and 0.5 mL of primer/probe mix each for the target and reference loci. The PCR program was set for 10 minutes at 95uC, followed by 40 cycles of 15 seconds at 95uC and 1 minute at 60uC. The FAM and VIC fluorescent signal intensity was followed in real time throughout the reaction to calculate the respective C T values. Copy number analysis was performed using the SDS v2.1 software package and the CopyCaller v1.0 software (Applied Biosystems). Statistical significance was computed using Fisher's exact test on the copy number called for each gene in HC and controls.
Ingenuity analysis
The most significantly differentially expressed genes were analyzed for gene ontology information and gene networks using the Ingenuity Pathway analysis software (Ingenuity Systems, Redwood City, CA, USA). Table 2 ). In the HC cases, 315 upregulated probes and 1041 downregulated probes were analyzed by hierarchical clustering (Fig. 1A) .
To determine candidate regions of genomic deletions, we identified sets of probes downregulated by at least 2fold and sequentially aligned along the human genome. This approach has previously been used to identify chromosomal deletion regions in neuroblastoma [22] . Thirteen regions with at least 2 consecutive probes, 10 of which had at least 3 consecutive probes, were identified (Table 1 ). Of the 13 regions, 2 regions stood out due to their large-fold decreases in expression. The 1st gene cluster consisted of 3 S100A genes at 1q21.3c: S100A8 (27.6-fold), S100A9 (24.5-fold), and S100A12 (210.7fold). The 2nd gene cluster consisted of 3 genes involved in cytokine signaling at 2q12.1a: IL1RL1 (or ST2; 26.9fold), IL18R1 (22.6-fold), and IL18RAP (23.2-fold). The mean downregulation of the 6 genes was 25.91-fold. Changes in RNA expression for the S100A gene cluster were confirmed by TaqMan quantitative PCR, with reductions in expression of S100A8 (239-fold), S100A9 (225-fold), and S100A12 (28-fold) (Fig. 1B) . We also confirmed reduced expression of IL1RL1 by TaqMan assay (252-fold), but changes in IL18R1 and IL18RAP expression were not measureable because the transcripts were not detectable by TaqMan QPCR in either cases or controls.
Sox6 and cytochrome b were not differentially expressed by WG-DASL in HC cases. However, in the Xp22 region, a total of 7 genes were differentially expressed in HC cases. Six genes (NLGN4X, P1GA, HCCS, SCML1, SMPX, PRDX4) were downregulated between 2-and 3-fold, and 1 gene (GPM6B) was upregulated (3.3-fold). These differences were likely not due to differences in male/female ratios, because only 39 of 975 (4%) probes on the X chromosome were significantly changed, and the majority of those (29 of 39, or 74%) were decreased in the cases, which had fewer males than the controls. Previous studies identified HCCS, AMELX, and ARHGAP6 as potential HC candidate genes; however, we did not observe reduced expression of AMELX and ARHGAP6, nor did we observe probes from 2 consecutive genes downregulated on the X chromosome [12] .
DNA copy number analysis of HC samples
Candidate deletion gene sets were validated by TaqMan copy number variation assays. Due to the limited quantity of DNA recovered from the FFPE samples, 3 of the downregulated genes (S100A12, IL18R1, IL1RL1) and a nearby control locus (PGLYRP3) that did not show decreased expression were chosen for the TaqMan assay. The calculated gene copy numbers for the 3 candidate genes were reduced in the HC samples when compared with the matching control samples (Fig. 1C and Table 2 ). Analysis of the copy number calls in HC cases versus controls by Fisher's exact test indicated that the frequency of haploid alleles compared with diploid alleles for S100A12 (P 5 0.002), IL18R1 (P 5 0.04), and IL1RL1 (P 5 0.04) were all significant, whereas the control gene PGLYRP3 was not (P 5 0.21). This result suggested that cases were haploinsufficient for these genes.
Ingenuity pathway analysis of HC samples
To gain insight into the biology of the observed changes in gene expression and DNA copy number in HC cases, we performed an ingenuity pathway analysis. Analysis of the complete set of altered genes (Supplementary Table 2 ) identified several significantly changed biological functions ( Table 3 ). The most significantly enriched functional annotation was for cell death (P 5 5.40E209, n 5 247). We also observed enrichment of 10 genes annotated for cardiovascular system development and function (P 5 7.47E203), namely CCL2, CD44, CX3CL1, DEFA3, HAS2, IL6, ITGB1, ITGB3, SERPINE1, and VEGFA.
We next constructed networks of genes altered in HC by ingenuity pathway analysis, using the sets of genes with alterations in gene expression and DNA copy number (Fig. 1D ). This network identified the signal transduction pathway connecting interleukin 33 (IL-33)/IL1RL1/p38-MAPK/S100A8-S100A9. Although it is not a part of 1 of the 13 regions with consecutive downregulated probes shown in Table 1 , we did observe a 2.4-fold decrease in expression of IL-33, as well as changes in IL1RPA, IRAK, Jnk, SMAD3, and NFKB1 (Supplementary Table 2 ).
DISCUSSION
Based on minimal evidence and extrapolation, several theories of HC pathogenesis (eg, cytochrome b mutation, SOX6 mutation, A8344G mDNA mutation) have been hypothesized [8] [9] [10] ; however, sufficient evidence has not been found to incriminate a specific etiology and pathogenesis for HC. Moreover, our current whole genome expression analysis failed to support mutations in cyctochrome b or SOX6.
The theory of Xp22 proposed by Bird and colleagues in 1994 [11] was carefully evaluated during our WG-DASL because of the prevalence of HC in female infants. Of the 91 genes altered in our HC cases that were annotated for cardiovascular disease by ingenuity pathway analysis ( Supplementary Table 3 ), only 2 are located on chromosome X, both of them on the q arm. We did identify 8 Xp22 chromosome genes to be differentially expressed in HC patients compared with control patients Figure 1 . A. Hierarchical clustering of 1356 up (red)-and down (green)-regulated probes in histiocytoid cardiomyopathy (HC) cases relative to controls. Probes shown had a minimum of 2-fold change and a false discovery rate of ,1%. Data were clustered using cluster and Java TreeView software [16] using average linkage clustering with Euclidean distance as the distance metric. B. TaqMan quantitative polymerase chain reaction validation of mRNA changes observed by whole (PRDX4, SMPX, SCML1, PIGA, HCCS, GPM6B, NLGN4X, and ZBED1). Based on the gene annotations and previous literature [23, 24] , all of these genes except ZBED1 have been detected as expressed in heart muscle, but in our study none were downregulated by more than 3-fold. Nevertheless, SMPX/Chisel can promote myocyte fusion and downregulation of PRDX4 may sensitize cancer cells to TRAIL-induced apoptosis [22, 25] . In addition, HCCS (22.1-fold) has been suggested as a potential HC candidate gene and is localized to the mitochondria [12] . Although the downregulation of this gene is not as significant as the reported candidate genes in our study (mean of 25.91-fold), the previous association of HCCS with HC in microphthalmia with linear skin defects syndrome suggests a possible link and might explain the female predominance of HC. Thus, although there were no 2 consecutive genes downregulated on the X chromosome and no single gene was downregulated more than 3-fold, we cannot definitively exclude any of these single genes as HC candidate genes. Further analysis must be performed to shed some light on this ambiguous relationship.
Here, we identified 2 functionally clustered groups of genes on 1q21.3c (S100A8, S100A9, S100A12) and 2q12.1a (IL1RL1, IL18R1, IL18RAP) as well as a single gene on 9p24.1b (IL-33) with reduced expression in HC lesions. Furthermore, DNA copy number decreases were confirmed for S100A12, IL1RL1, and IL18R1. To evaluate direct and indirect gene networks, we used ingenuity pathway analysis to map biological pathways that linked these genes. All genes were directly or indirectly linked within one common network. These results suggest that the IL-33/IL1RL1/p38 MAPK/S100A8&9 axis is downregulated in HC cardiac tissue (Fig. 1D ).
Transmembrane receptor IL1RL1(ST2) is a member of the IL-1 receptor superfamily that serves as a gateway to many proinflammatory signaling pathways [26] . IL-33 was recently identified as the functional ligand for IL1RL1(ST2) [27] , and this discovery has led to many new insights into cardiovascular pathology.
The IL-33/IL1RL1(ST2) axis has been identified as a crucial cardioprotective pathway in several studies [28, 29] . IL-33/IL1RL1(ST2) signaling is capable of activating p38 MAPK and nuclear factor-kB signaling pathways [27] . In 1998, Zechner and colleagues [30] reported that P38-dependent NF-kB activation aids in protecting myocardial cells from undergoing apoptosis. Additionally, IL-33 is produced by cardiac fibroblasts in response to biomechanical stress, and its signaling through IL1RL1(ST2) negatively regulates cardiomyocyte hypertrophy and cardiac fibrosis [31] . Activation of this pathway has also been shown to prevent cardiomyocyte apoptosis and improve cardiac function after myocardial infarction [26] . Finally, in 2010 Yin and colleagues [32] identified a potential role for IL-33/IL1RL1(ST2), signaling the induction and maintenance of cardiac transplant tolerance [32] .
Activation of the IL-33 pathway is also associated with inflammation [33] and fibrosis [34] . Thus, inactivation of this pathway would be consistent with histopathological changes in HC that lack inflammation and fibrosis. However, to our knowledge, there is no known connection between the IL-33 pathway and mitochondria or oncocytic changes. S100 calcium-binding proteins S100A8, S100A9, and S100A12 were also downregulated in HC. S100A8 and S100A9 are found both intracellularly and extracellularly and are, therefore, capable of exerting both autocrine and intracellular effects [31, 32] . Together, S100A8 and r genome cDNA-mediated annealing, selection, extension, and ligation (WG-DASL) assay in candidate HC genes. PGLYRP3 (1q21.3c) and S100A7 are the 2 flanking genes for S100A9/S100A12/S100A8 that were not changed in the WG-DASL assay and were included as negative control assays. IL1RL2 was the control flanking region for IL1RL1. Data for IL18R1 and IL18RAP are not shown because they were not detected in either the case or the control samples. C. DNA copy number analysis results. The TaqMan assay revealed reduced copy numbers for genes S100A12, IL18R1, and IL1RL1 in HC samples (blue bars) compared with control samples (red bars). The control locus, PGLYRP3, ,50 kb from the S100A9 gene, did not show significant changes in copy number. D. Network of altered candidate genes in HC obtained by ingenuity pathway analysis. Solid lines represent direct interactions. Dotted lines represent indirect interactions. The node indicates the class of the molecule. The intensity of the node color indicates the degree of up (red)-or down (green)-regulation. Jnk is part red and part green because it represents a group of kinases, some of which were upregulated (MAPK10) and others that were downregulated (MAP2K4). Although IL1RPA, IRAK, Jnk, SMAD3, and NFKB1 were downregulated, they were not members of sets of adjacent genes along the genome. S100A9 form the ubiquitous heterodimer calprotectin, a proinflammatory cytokine, and this protein complex has been shown to exert a proapoptotic effect [35] . Furthermore, like IL-33/ST2 signaling, there is strong evidence that extracellular S100A8/A9 signaling via advanced glycation end products receptor results in p38 MAPK activation of NF-kB [36] . Furthermore, S100A8 and S100A9 are known to be important in heart function [37] . In the heart, inflammatory-challenged cardiac cells secrete S100A8/A9 and likely signal through advanced glycation end products receptor to suppress cardiac contractility [37] . Finally, although its function is still poorly understood, S100A12 is also implicated in cardiovascular pathology, and its downregulation has been shown to suppress inflammatory and apoptosis pathways [35, 38] . IL18R1 and IL18RAP are the receptor and accessory protein, respectively, for the prohypertrophic cytokine IL-18. In a mouse model, signaling of IL-18 via IL18R1 and IL18RAP has been shown to induce cardiomyocyte hypertrophy.
In conclusion, our data suggest a potential role for the downregulation of the IL-33/IL1RL1(ST2)/p38-MAPK/ S100A8-S100A9 signaling cascade in the pathogenesis of HC. One potential net effect would be reduced NF-kB activation, supported by the decreased NF-kB activity identified in our study. This in turn could result in reduced survival of cardiac myocytes, ultimately resulting in cardiac failure during development. These studies provide the starting point for examination of several candidate genes on 1q21.3c and 2q12.1a for inherited mutations that predispose patients to HC.
Future plans are to analyze remaining HC registry cases to confirm the present findings. Additionally, we plan to collect and analyze blood from the siblings and parents of HC patients to better understand the pathogenesis and inheritance pattern.
